{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T10:09:30Z","timestamp":1760609370289,"version":"3.37.3"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,6,5]],"date-time":"2021-06-05T00:00:00Z","timestamp":1622851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,6,5]],"date-time":"2021-06-05T00:00:00Z","timestamp":1622851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s00296-021-04902-7","type":"journal-article","created":{"date-parts":[[2021,6,5]],"date-time":"2021-06-05T06:02:54Z","timestamp":1622872974000},"page":"1503-1507","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["COVID-19 in patients with gout on colchicine"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9383-5722","authenticated-orcid":false,"given":"Eleftherios","family":"Pelechas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6880-553X","authenticated-orcid":false,"given":"Vassiliki","family":"Drossou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5193-2284","authenticated-orcid":false,"given":"Paraskevi V.","family":"Voulgari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2232-0326","authenticated-orcid":false,"given":"Alexandros A.","family":"Drosos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,5]]},"reference":[{"key":"4902_CR1","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","volume":"395","author":"F Zhou","year":"2020","unstructured":"Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z et al (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395:1054\u20131062. https:\/\/doi.org\/10.1016\/S0140-6736(20)30566-3","journal-title":"Lancet"},{"key":"4902_CR2","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41584-020-0418-0","volume":"16","author":"PC Robinson","year":"2020","unstructured":"Robinson PC, Yazdany J (2020) The COVID-19 global rheumatology alliance: collecting data in a pandemic. Nat Rev Rheumatol 16:293\u2013294. https:\/\/doi.org\/10.1038\/s41584-020-0418-0","journal-title":"Nat Rev Rheumatol"},{"key":"4902_CR3","doi-asserted-by":"publisher","first-page":"e52","DOI":"10.1016\/S0140-6736(20)30558-4","volume":"395","author":"T Wang","year":"2020","unstructured":"Wang T, Du Z, Zhu F, Cao Z, An Y, Gao Y et al (2020) Comorbidities and multi-organ injuries in the treatment of COVID-19. Lancet 395:e52. https:\/\/doi.org\/10.1016\/S0140-6736(20)30558-4","journal-title":"Lancet"},{"key":"4902_CR4","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1136\/annrheumdis-2019-216653","volume":"79","author":"A Sepriano","year":"2020","unstructured":"Sepriano A, Kerschbaumer A, Smolen JS, van der Heijde D, Dougados M, van Vollenhoven R et al (2020) Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 79:760\u2013770. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216653","journal-title":"Ann Rheum Dis"},{"key":"4902_CR5","doi-asserted-by":"crossref","first-page":"175","DOI":"10.55563\/clinexprheumatol\/r3k9l6","volume":"38","author":"F Ferro","year":"2020","unstructured":"Ferro F, Elefante E, Baldini C, Bartoloni E, Puxeddu I, Talarico R et al (2020) COVID-19: the new challenge for rheumatologists. Clin Exp Rheumatol 38:175\u2013180","journal-title":"Clin Exp Rheumatol"},{"key":"4902_CR6","doi-asserted-by":"publisher","first-page":"259","DOI":"10.31138\/mjr.31.3.259","volume":"31","author":"E Pelechas","year":"2020","unstructured":"Pelechas E, Drossou V, Voulgari PV, Drosos AA (2020) Anti-rheumatic drugs for the fight against the novel coronavirus infection (SARS-CoV-2): what is the evidence? Mediterr J Rheumatol 31:259\u2013267. https:\/\/doi.org\/10.31138\/mjr.31.3.259","journal-title":"Mediterr J Rheumatol"},{"key":"4902_CR7","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1136\/annrheumdis-2020-217871","volume":"79","author":"M Gianfrancesco","year":"2020","unstructured":"Gianfrancesco M, Hyrich KL, Al-Adely S, Carmona L, Danila MI, Gossec L et al (2020) Characteristics associated with hospitalization for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry. Ann Rheum Dis 79:859\u2013866. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217871","journal-title":"Ann Rheum Dis"},{"key":"4902_CR8","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1136\/annrheumdis-2020-217424","volume":"79","author":"S Monti","year":"2020","unstructured":"Monti S, Balduzzi S, Delvino P, Bellis E, Quadrelli VS, Montecucco C (2020) Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Ann Rheum Dis 79:667\u2013668. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217424","journal-title":"Ann Rheum Dis"},{"key":"4902_CR9","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1002\/art.41456","volume":"72","author":"RH Haberman","year":"2020","unstructured":"Haberman RH, Castillo R, Chen A, Yan D, Ramirez D, Sekar V et al (2020) COVID-19 in patients with inflammatory arthritis: a prospective study on the effects of comorbidities and disease-modifying antirheumatic drugs on clinical outcomes. Arthritis Rheumatol 72:1981\u20131989. https:\/\/doi.org\/10.1002\/art.41456","journal-title":"Arthritis Rheumatol"},{"key":"4902_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00296-021-04818-2","volume":"3","author":"MP Migkos","year":"2021","unstructured":"Migkos MP, Kaltsonoudis E, Pelechas E, Drossou V, Karagianni PG, Kavvadias A (2021) Use of conventional synthetic and biologic disease- modifying anti-rheumatic drugs in patients with rheumatic diseases contracting COVID-19: a single-center experience. Rheumatol Int Mar 3:1\u20137. https:\/\/doi.org\/10.1007\/s00296-021-04818-2","journal-title":"Rheumatol Int Mar"},{"key":"4902_CR11","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41584-020-00562-2","volume":"17","author":"KL Hyrich","year":"2021","unstructured":"Hyrich KL, Machado PM (2021) Rheumatic disease and COVID-19: epidemiology and outcomes. Nat Rev Rheumatol 17:71\u201372. https:\/\/doi.org\/10.1038\/s41584-020-00562-2","journal-title":"Nat Rev Rheumatol"},{"key":"4902_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219498","author":"A Strangfeld","year":"2021","unstructured":"Strangfeld A, Schafer M, Gianfrancesco MA, Lawson-Tovey S, Liew JW, Ljung L et al (2021) Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 global rheumatology alliance physician-reported registry. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/annrheumdis-2020-219498","journal-title":"Ann Rheum Dis"},{"unstructured":"US National Library of Medicine. Clinical Trials. Colchicine coronavirus SARS-CoV-2 Trial (COLCORONA) (COVID-19). NCT04322682. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04322682. Accessed Mar 2021","key":"4902_CR13"},{"key":"4902_CR14","doi-asserted-by":"publisher","first-page":"e2013136","DOI":"10.1001\/jamanetworkopen.2020.13136","volume":"3","author":"SG Deftereos","year":"2020","unstructured":"Deftereos SG, Giannopoulos G, Vrachatis DA, Siasos GD, Giotaki SG, Gargalianos P et al (2020) Effect of colchicine vs standard care on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with coronavirus disease 2019: the GRECCO-19 randomized clinical trial. JAMA Netw Open 3:e2013136. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.13136","journal-title":"JAMA Netw Open"},{"key":"4902_CR15","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1007\/s10067-020-05144-x","volume":"39","author":"MC Cure","year":"2020","unstructured":"Cure MC, Kucuk A, Cure E (2020) Colchicine may not be effective in COVID-19 infection; it may even be harmful? Clin Rheumatol 39:2101\u20132102. https:\/\/doi.org\/10.1007\/s10067-020-05144-x","journal-title":"Clin Rheumatol"},{"key":"4902_CR16","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.amjmed.2014.12.010","volume":"128","author":"A Sobodnick","year":"2015","unstructured":"Sobodnick A, Shah B, Pillinger MH, Krasnokutsky S (2015) Colchicine: old and new. Am J Med 128:461\u2013470. https:\/\/doi.org\/10.1016\/j.amjmed.2014.12.010","journal-title":"Am J Med"},{"key":"4902_CR17","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.semarthrit.2015.06.013","volume":"45","author":"YY Leung","year":"2015","unstructured":"Leung YY, Hui LLY, Kraus VB (2015) Colchicine\u2014update on mechanisms of action and therapeutic uses. Semin Arthritis Rheum 45:341\u2013350. https:\/\/doi.org\/10.1016\/j.semarthrit.2015.06.013","journal-title":"Semin Arthritis Rheum"},{"key":"4902_CR18","doi-asserted-by":"publisher","first-page":"i4","DOI":"10.1093\/rheumatology\/kex453","volume":"57","author":"A Slobodnick","year":"2018","unstructured":"Slobodnick A, Shah B, Krasnokutsky S, Pillinger MH (2018) Update on colchicine, 2017. Rheumatology (Oxford) 57:i4\u2013i11. https:\/\/doi.org\/10.1093\/rheumatology\/kex453","journal-title":"Rheumatology (Oxford)"},{"key":"4902_CR19","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/j.jacc.2013.08.726","volume":"62","author":"S Deftereos","year":"2013","unstructured":"Deftereos S, Giannopoulos G, Papoutsidakis N, Panagopoulou V, Kossyvakis C, Raisakis K et al (2013) Colchicine and the heart: pushing the envelope. J Am Coll Cardiol 62:1817\u20131825. https:\/\/doi.org\/10.1016\/j.jacc.2013.08.726","journal-title":"J Am Coll Cardiol"},{"key":"4902_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.hjc.2020.11.012","author":"DA Vrachatis","year":"2020","unstructured":"Vrachatis DA, Giannopoulos GV, Giotaki SG et al (2020) Impact of colchicine on mortality in patients with COVID-19: a meta- analysis. Hellenic J Cardiol. https:\/\/doi.org\/10.1016\/j.hjc.2020.11.012","journal-title":"Hellenic J Cardiol"},{"key":"4902_CR21","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/ehjcvp\/pvaa033","volume":"6","author":"S Deftereos","year":"2020","unstructured":"Deftereos S, Giannopoulos G, Vrachatis DA, Siasos G, Giotaki SG, Cleman M et al (2020) Colchicine as a potent anti-inflammatory treatment in COVID-19: can we teach an old dog new tricks? Eur Heart J Cardiovasc Pharmacother 6:255. https:\/\/doi.org\/10.1093\/ehjcvp\/pvaa033","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"4902_CR22","doi-asserted-by":"publisher","first-page":"e001455","DOI":"10.1136\/rmdopen-2020-001455","volume":"7","author":"MI Lopes","year":"2021","unstructured":"Lopes MI, Bonjorno LP, Giannini MC, Amaral NB, Menezes PI, Dib SM et al (2021) Beneficial effects of colchicine for moderate to severe COVID-19: a randomized, double-blinded, placebo-controlled clinical trial. RMD Open 7:e001455. https:\/\/doi.org\/10.1136\/rmdopen-2020-001455","journal-title":"RMD Open"},{"key":"4902_CR23","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/s0966-842x(00)01936-3","volume":"9","author":"BT Cookson","year":"2001","unstructured":"Cookson BT, Brennan MA (2001) Pro-inflammatory programmed cell death. Trends Microbiol 9:113\u2013114. https:\/\/doi.org\/10.1016\/s0966-842x(00)01936-3","journal-title":"Trends Microbiol"},{"key":"4902_CR24","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3389\/fmicb.2019.00050","volume":"10","author":"IY Chen","year":"2019","unstructured":"Chen IY, Moriyama M, Chang MF, Ichinohe T (2019) Severe acute respiratory syndrome coronavirus viroporin 3a activates the NLRP3 inflammasome. Fron Microbiol 10:50. https:\/\/doi.org\/10.3389\/fmicb.2019.00050","journal-title":"Fron Microbiol"},{"key":"4902_CR25","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1136\/annrheumdis-2020-219174","volume":"80","author":"AZ Reyes","year":"2021","unstructured":"Reyes AZ, Hu KA, Teperman J, Muskardin TLW, Tardif JC, Shah B, Pillinger MH (2021) Ann Rheum Dis 80:550\u2013557. https:\/\/doi.org\/10.1136\/annrheumdis-2020-219174","journal-title":"Ann Rheum Dis"},{"key":"4902_CR26","doi-asserted-by":"publisher","first-page":"e39","DOI":"10.1136\/annrheumdis-2020-217882","volume":"80","author":"S Kobak","year":"2021","unstructured":"Kobak S (2021) COVID-19 infection in a patient with FMF: does colchicine have a protective effect? Ann Rheum Dis 80:e39","journal-title":"Ann Rheum Dis"},{"key":"4902_CR27","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1136\/annrheumdis-2020-218707","volume":"80","author":"R Bourguiba","year":"2021","unstructured":"Bourguiba R, Delplanque M, Vinit C et al (2021) Clinical course of COVID-19 in a cohort of 342 familial Mediterranean fever patients with a long-term treatment by colchicine in a French endemic area. Ann Rheum Dis 80:539\u2013540. https:\/\/doi.org\/10.1136\/annrheumdis-2020-218707","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-021-04902-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-021-04902-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-021-04902-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,30]],"date-time":"2022-12-30T00:25:46Z","timestamp":1672359946000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-021-04902-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,5]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["4902"],"URL":"https:\/\/doi.org\/10.1007\/s00296-021-04902-7","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"type":"print","value":"0172-8172"},{"type":"electronic","value":"1437-160X"}],"subject":[],"published":{"date-parts":[[2021,6,5]]},"assertion":[{"value":"17 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}